Scancell Holdings Plc Presents Moditope Data at Immunotherapy Conference

TIDMSCLP

Scancell Holdings Plc

11 September 2017

11 September 2017

Scancell Holdings Plc

("Scancell" or the "Company")

Scancell Presents Moditope(R) Data at the Third CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference

Scancell Holdings plc, ('Scancell' or the 'Company') the developer of novel immunotherapies for the treatment of cancer, announces that it has presented data on the Company's Moditope(R) platform at the Third CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference in Mainz, Germany, 6-9 September 2017.

Scancell's Moditope(R) platform stimulates powerful anti-tumour T-cell responses against citrullinated peptides which destroy tumours without toxicity.

Prof. Lindy Durrant, Ph.D., Chief Scientific Officer of Scancell and Professor of Cancer Immunotherapy, University of Nottingham, presented two posters on Friday 8 September 2017 at 6.15pm CET, in poster session B.

Prof. Durrant commented:

"We were pleased to be selected to present our latest data on Moditope(R) at this year's prestigious International Cancer Immunotherapy Conference, showing that our lead product from the Moditope(R) platform, Modi-1, induced strong anti-tumour immunity in pancreatic, lung, ovarian and melanoma models with up to 100% survival.

"Our poster in collaboration with ISA Pharmaceuticals showed that Modi-1 conjugated to synthetic TLR1/2 agonists generated an anti-tumour response at up to 100-fold lower doses than Modi-1 alone and that these conjugated peptides induced a memory response against tumour re-challenge.

"These results suggest that Modi-1 conjugated directly to TLR agonists could be a powerful new approach to the treatment of cancer."

Both posters will be made available on the Investor section of the Company's website:

https://www.scancell.co.uk/investors

For Further Information:

 
 Dr John Chiplin, Executive 
  Chairman                                          [phone] 
  Dr Richard Goodfellow,       Scancell Holdings     [phone] 
  CEO                           Plc                  1000 
 
 Freddy Crossley (Corporate 
  Finance) 
  Tom Salvesen (Corporate      Panmure Gordon       [phone] 
  Broking)                      & Co                 2500 
 
                                                    [phone] 
 Mo Noonan/Simon Conway        FTI Consulting        1000 
 

About Scancell

Scancell is developing novel immunotherapies for the treatment of cancer based on its ImmunoBody(R) and Moditope(R) technology platforms.

Scancell's first ImmunoBody(R), SCIB1 is being developed for the treatment of melanoma. Data from the Phase 1/2 clinical trial demonstrate that SCIB1, when used as monotherapy, has a marked effect on tumour load, produces a melanoma-specific immune response and highly encouraging survival trend without serious side effects. In patients with resected disease there is increasing evidence to suggest that SCIB1 may delay or prevent disease recurrence.

Scancell's ImmunoBody(R) vaccines target dendritic cells and stimulate both parts of the cellular immune system: the helper cell system where inflammation is stimulated at the tumour site and the cytotoxic T-lymphocyte or CTL response where immune system cells are primed to recognise and kill specific cells.

Pre-clinical data on a combination of SCIB1 or SCIB2 and checkpoint inhibition (blockade of the PD-1 or CTLA-4 immune checkpoint pathways) have shown enhanced tumour destruction and significantly longer survival times than when either treatment was used alone. Experimental data suggests that the high avidity T cells induced by ImmunoBody(R) vaccines increase expression of PDL-1 on the tumour cell surface, thereby making the tumours more sensitive to checkpoint inhibitor drugs. Re-challenging animals with tumour cells after SCIB1 treatment resulted in 100% survival suggesting that ImmunoBody(R) induces a powerful memory response. Such an effect has not been observed with checkpoint inhibitors.

Scancell has also identified and patented a series of modified epitopes that stimulate the production of killer CD4+ T cells that destroy tumours without toxicity. The Directors believe that the Moditope(R) platform could play a major role in the development of safe and effective cancer immunotherapies in the future.

About the CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference

The Cancer Research Institute (CRI), the Association for Cancer lmmunotherapy (CIMT), the European Academy of Tumor Immunology (EATI), and the American Association for Cancer Research (AACR) are proud to join forces once again to sponsor the Third International Cancer lmmunotherapy Conference.

The 2017 meeting will take place at the Rheingoldhalle Congress Center in Mainz/Frankfurt, Germany from September 6-9, 2017. The program will focus on "Translating Science into Survival," and feature talks from more than 60 leaders in the field covering all areas of inquiry in cancer immunology and immunotherapy, including: neoantigens and vaccines, novel mechanisms of immunosuppression and immune evasion, biomarkers, microbiota, oncolytic viruses, new agents and their mode of action, combination therapies, adoptive cell therapies, new checkpoints, non-checkpoint immunotherapies, and the tumour microenvironment.

This meeting will provide an unparalleled opportunity for teaching, learning, and networking among all stakeholders in the field: scientists, clinicians, regulators, drug developers, and patient advocates.

This information is provided by RNS

The company news service from the London Stock Exchange

END

NRASSLFDUFWSEFU

(END) Dow Jones Newswires

September 11, 2017 02:01 ET (06:01 GMT)